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Abstract
Generation of myeloid and lymphoid cells from progenitors involves dynamic changes in
transcription factor expression and use, and disruption of hematopoietic transcription factor
function and expression can contribute to leukemic transformation. PU.1 and Ikaros are pivotal
factors whose expression and utilization are dynamically altered during hematopoietic
development. Here, we demonstrate that expression of PU.1, encoded by the Sfpi1 gene, is
divergently regulated by Ikaros in distinct cell-type-specific contexts. ChIP analysis and functional
perturbations revealed that Ikaros can directly repress or activate Sfpi1 transcription via different
PU.1 cis-elements, with PU.1 and Ikaros collaborating at myeloid-specific elements but not at
other elements. Our results thus shed light on how PU.1 and Ikaros can act as lineage competency
factors to facilitate both myeloid and lymphoid developmental programs.
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Introduction
The proto-oncogene PU.1, upregulated in virally-induced erythroleukemias, is an Ets family
transcription factor encoded by the Sfpi1/Spi-1 gene (1). PU.1 plays critical roles in multiple
hematopoietic cell types (2, 3) and has emerged as a key determinant regulating cell-type
specification.Higher PU.1 dosage restricts erythrocyte specification and enables generation
of committed myeloid progenitors or joint myeloid/lymphoid progenitors, the lymphoid-
primed multipotent precursors (LMPP) (2, 4). Expressed at the LMPP stage, PU.1 levels rise
in myeloid progenitors, but fall in pre-pro-B-cells (5, 6). Differences in PU.1 level strongly
affect specification of myeloid vs. B-cells from LMPPs (7). However, PU.1 deficiency
blocks both myeloid and B-cell development and reduced PU.1 dosage promotes AML (8,
9). Thus, precise transcriptional controls of PU.1 expression are required.
The mechanisms controlling PU.1 expression as LMPPs become myeloid or B-cells remain
unclear. PU.1 positively autoregulates by binding the Sfpi1 promoter and URE, a compound
enhancer element located ~14 kb upstream of the Sfpi1 transcriptional start site (10, 11, 12,
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13). Additional myeloid-specific enhancers have also been found between the URE and the
promoter (14, 15). A recently proposed gene regulatory network model for the differential
control of PU.1 expression in B-cell versus myeloid specification suggests that attenuation
of PU.1 autoregulation by two transcription factors, Gfi-1 and Ikaros, can regulate these cell
fate decisions (13).
Many cell types that depend on PU.1 also depend on Ikaros. However, the optimal ratios of
these two factors diverge in myeloid and B lymphoid lineages (16), and it is unclear whether
Ikaros and PU.1 work collaboratively or antagonistically. Ikaros is a lineage determinant
with a critical role in priming the lymphoid developmental program in HSCs and
progenitors, and mice lacking Ikaros also develop myeloid hyperproliferation (17, 18). The
dominant negative Ikaros isoform 6 has been linked with AML (19). Although PU.1 and
Ikaros collaborate to control at least one important target in LMPPs (20, 21),genetic
evidence suggests that Ikaros opposes PU.1 to support B-cell development over alternative
myeloid programs (13, 22). Indeed, expression of a dominant negative version of Ikaros in
erythroid cells increased PU.1 levels (23). Because of the central position of both factors in
lymphoid developmental gene networks, and their roles in leukemia, it is crucial to resolve
whether Ikaros is indeed a direct repressor of PU.1.
Here, we show that Ikaros binds distinct subsets of Sfpi1 cis-elements, including the URE,
in myeloid and B lineage cells. Whereas Ikaros suppresses URE activity in pre-B-cells, we
show that Ikaros is a cell-type-specific URE activator in myeloid cells. Furthermore, we find
that Ikaros, PU.1 and RNA polymerase II are co-recruited and collaborate to drive activation
through additional myeloid-specific enhancers. These results resolve the bifunctional role of
Ikaros in PU.1 regulation through lineage-specific recruitment to distinct cis-elements that
direct both Ikaros and PU.1 functional specificity.
Results and Discussion
A ~3 kb DNA fragment, CE5-CE3, is a myeloid enhancer lacking B-cell regulatory function
After PU.1 is expressed in LMPPs, its levels diverge between myeloid and lymphoid cells
(5). We recently described a Sfpi1 cis-regulatory region, CE5-CE3, which had cell-type-
specific functions. The CE5 element, on its own or as part of CE5-CE3, was an enhancer in
a myeloid cell line but not in a pro-T-cell line (14). To determine whether this function is
myeloid specific or common to all PU.1 expressing cells, we tested CE5-CE3 function in B
lineage cells.
Reporter constructs were made to test segments of the Sfpi1 upstream region joined to the
Sfpi1 promoter element, CE1 (Fig 1a). In NFS-25 pre-B-cells the construct containing
CE5-3 (L5-3) generated similar luciferase expression as L1, the promoter only construct, but
in RAW264.7 myeloid cells L5-3 produced strongly enhanced reporter expression (Fig. 1b).
In contrast, the conserved URE elements CE9 and CE8 within the L98 reporter enhanced
luciferase expression similarly in pre-B and myeloid cells alike (Fig. 1b). Cell-type-specific
CE5-CE3 activity was also demonstrated in a chromatin context in stably transfected cell
lines. We tested reporters comprising the URE and CE7/6 either without CE5-CE3 (L9-6) or
with it (L9-3). L9-6 generated similar luciferase expression in pre-B and myeloid cells.
However, L9-3 gave stronger reporter activity only in the myeloid cells (Fig. 1c), implying
that CE5-CE3 enhancer activity is myeloid restricted.
CE5 and CE7/6 are myeloid-restricted PU.1 target elements
To identify potentially important transcription factor binding sites within CE5, we used
TRANSFAC to analyze regions of CE5 that were conserved in multigenome alignments. As
the CE7/6 region may contribute to myeloid specific PU.1 regulation (15), we also examined
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CE7/6. The most frequently predicted sites in both CE5 and CE7/6 are overlapping Ikaros
and Ets family sites (Fig. 1d). Ikaros is a bifunctional transcription factor able to activate or
repress transcription, and Ikaros can compete with Ets factors for the same sites (24). Ikaros,
which is required for B-cell development, might constrain PU.1 expression by blocking PU.
1 autoregulation through the URE (13). However, in our myeloid and B-cell lines the URE
drove similar levels of reporter activity. Thus, the myeloid specific enhancer activity of
CE5-CE3 and its predicted Ets family sites suggested that myeloid restricted PU.1
autoregulation could contribute to the functional specificity of CE5-CE3.
PU.1 chromatin immune precipitation (ChIP) in fact revealed cell-type-specific patterns of
PU.1 occupancy at Sfpi1 regions. PU.1 bound the promoter region (CE1) in myeloid cells
(Fig. 2a, red panel) as previously reported (11), but that binding was weak compared with
the strong PU.1 binding at the URE elements CE9 and CE8 in these cells (Fig. 2a, red
panel). PU.1 also bound CE8 in pre-B-cells (Fig. 2a, blue panel), as well as known PU.1
target genes, Mef2c and Il7r, in both PU.1-expressing cell lines (red and blue panels)(25,
26); Adh.2C2 pro-T cells, which lack PU.1, showed no binding (green panel). However,
only in the myeloid cells was strong PU.1 binding found at CE5 and CE7/6 (Fig.2a, arrows).
PU.1’s failure to bind some Sfpi1 regions in pre-B-cells could be due to other Ets factors
competitively binding in preference to PU.1. However, while three Ets factors expressed in
the cell types examined, Elf-1, Ets-1, and GABPα, could bind some PU.1 target sites, only
PU.1 bound strongly to CE7-CE5 (Fig. 2b-2d)(27).
The URE can recruit RNA polymerase II (Pol II)-containing complexes in PU.1-expressing
cells (28, 29). Pol II association with other Sfpi1 regions was also cell-type-specific. Pol II
occupied CE8 in all cell lines tested, but bound to the promoter (CE1) only in PU.1-
expressing cells (Fig. 2e). Significantly, however, Pol II bound CE5 and CE7/6 only in the
myeloid cells (Fig. 2e, arrows). These results support a functional role for CE5 in myeloid
specific PU.1 regulation as well as CE7/6 (15).
Cell-type-specific binding of Ikaros at Sfpi1 cis-elements
The presence of numerous predicted Ikaros binding sites across CE5, and the absence of PU.
1 binding in the pre-B-cell line, suggested that Ikaros might compete with PU.1 to block PU.
1 autoregulation. Anti-Ikaros ChIP iindeed revealed cell-type-restricted patterns of Ikaros
binding. Ikaros bound CE9 and CE8 in macrophages and pre-B-cells (Fig. 3a). Much lower
Ikaros binding was seen in the pro-T-cell line, despite high Ikaros expression (discussed
below). Additionally, Ikaros uniquely bound CE10 in pre-B-cells, a region that may
participate in Sfpi1 repression in erythroid cells (30)(Fig. 3a, blue arrow). Surprisingly,
Ikaros did bind CE7/6 and CE5 too, but only in myeloid cells (Fig. 3a, red arrows).
The cell-type-specific Ikaros association patterns observed imply distinct, context-specific
rules for Ikaros recruitment. PU.1 but not Ikaros bound Il7r in RAW264.7 (Fig. 2a), whereas
Ikaros occupied Il7r in Adh.2C2 cells that lack PU.1 expression (Fig. 3a, green arrow). Thus
Ikaros binding strength is determined separately from PU.1 at Il7r. In contrast, the unique
pattern of Ikaros occupancy of Sfpi1 sites in the myeloid cells suggested that Ikaros
recruitment to CE5 and CE7/6 in RAW264.7 cells might involve co-occupancy with bound
PU.1.
PU.1 can recruit Ikaros DNA binding
To test whether PU.1 binds concomitantly with Ikaros at the CE5 sites, a DNA probe was
made from the CE5 region (CE5-P2) to span adjacent sites predicted to bind PU.1 and
Ikaros (Fig. 1d, box). The CE5-P2 probe nucleated myeloid specific complexes in gel shift
experiments (Fig. 3b, lanes 1-6 vs. 7-12; M1, M2, and M3). M1, M2, and M3 contained PU.
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1, because anti-PU.1 antibody supershifted those complexes (Fig. 3b, lane 5). Additionally,
an anti-Ikaros antibody blocked formation of the PU.1 containing M1 complex (lane 6).
Mutation of the overlapping PU.1/Ikaros site (mutated in CE5-P2m1) destroyed the ability
to compete for the myeloid complexes (lanes 2, 3). Although mutation of the Ikaros specific
site in CE5-P2m2 did not prevent competition for M1, M2, and M3 (lane 4), it did prevent
probe CE5-P2m2 from nucleating these complexes itself (lanes 13-18). Thus distinct PU.1
and Ikaros binding sites in CE5 may collaborate to form myeloid-specific PU.1-Ikaros
complexes. Similar results were found with a probe spanning predicted Ikaros-PU.1-Ikaros
sites in CE7/6 (data not shown).
Ikaros could be recruited to CE5-P2 using in vitro translated PU.1 generated in a
reticulocyte lysate transcription/translation system. Lysate containing PU.1 could form
complex M1 while lysate lacking PU.1 could not (Fig. 3c, lanes 2, 3; arrow). In this system,
which contains endogenous Ikaros (31), the M1 complex was sensitive to both anti-PU.1 and
anti-Ikaros antibodies (lanes 8, 9). Furthermore, formation of the M1 complex by PU.1 was
also blocked by addition of in vitro translated “Plastic”, a dominant negative point mutant of
Ikaros that heterodimerizes with wildtype Ikaros family members to inhibit DNA binding
(32)(lane 6). Thus PU.1 and Ikaros binding to CE5 can be coordinate, not competitive.
Effect of PU.1 dose on recruitment of PU.1 and Ikaros to Sfpi1 sites in vivo
The CE5 site where PU.1 and Ikaros co-bind in myeloid cells is not bound by the myeloid
driver C/EBPα (15). We therefore tested whether high dose PU.1 alone is sufficient to bind
and recruit Ikaros to this site. Adh.2C2 pro-T-cells, which normally express no PU.1 but ≥2x
more Ikaros protein than RAW264.7 cells (Fig. 3d), were retrovirally transduced with PU.1
(~60% of cells transduced, data not shown), then analyzed by ChIP to track occupancy
patterns of endogenous Ikaros and the exogenous PU.1. Transduced Adh.2C2 cells
expressed >2x more PU.1 RNA than RAW264.7 cells (Fig. 3e), and the ectopic PU.1
strongly bound to Mef2c, Il7r and both URE elements (Fig. 3f). The presence of PU.1 in PU.
1-transduced Adh.2C2 cells now enabled Ikaros to be recruited to CE9 (Fig. 3g), in contrast
to untransduced cells (Fig. 3a). Ikaros also bound Il7r more strongly (Fig. 3g). Additionally,
Pol II now also bound CE9 and Il7r in the Adh.2C2+PU.1 cells (Fig. 3h).
However, despite the high dose, PU.1 did not bind CE5 and could only weakly bind CE7/6,
similar to NFS-25 cells. Similarly, the myeloid-specific elements where PU.1 and Ikaros
bind together were not occupied efficiently by either factor in the PU.1-overexpressing
lymphoid cells. Thus, high-level PU.1 is not the sole determinant involved in cell-type-
specific CE5 and CE7/6 activity.
PU.1 and Ikaros binding sites are required for CE5 enhancer activity
Gel shift analysis resolved potential PU.1 and Ikaros target sites within CE5 that might be
required for CE5 enhancer activity. We tested the functional contribution of those sites by
constructing additional L5-3 reporters harboring mutations in these CE5 sites (Fig. 4a).
When the m1 and m2 sites, required for the PU.1- and Ikaros-containing M1 complex (Fig.
3b), were mutated in L5-3m1-2, enhancer activity in myeloid cells was abolished (Fig. 4a).
Additionally, mutation of another overlapping PU.1/Ikaros site in CE5 also abolished CE5-3
enhancer activity (L5-3m4). In contrast, mutation of a predicted C/EBP family site
(L5-3m3) did not affect reporter activity. These results indicate that joint PU.1 and Ikaros
sites are required at CE5 for its myeloid cell-specific enhancer function.
PU.1 mediates CE7/6-CE5 enhancer activity
To establish whether the myeloid-specific PU.1 binding is functional, we compared the
effects of PU.1 knockdown on the activities of L98 and a reporter that contains both CE7/6
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and CE5 joined to the PU.1 promoter (L7-5). Antisense morpholinos (E1 and E2) that target
different PU.1 exon/intron boundaries eliminated detectable PU.1 protein expression in
myeloid cells as compared with a nonspecific control morpholino (Fig. 4b). PU.1
knockdown not only reduced L98 activity ~40% (Fig. 4c), as expected, but also completely
abolished the enhancer function of L7-5 (Fig. 4c). Thus while the URE is PU.1 responsive
but partially PU.1 independent, CE7-CE5 strictly requires PU.1 for enhancer activity in
these myeloid cells.
Lineage-specific effects of Ikaros on Sfpi1 cis-elements: positive regulation in myeloid
cells but inhibitory activity in pre-B-cells
To determine why Ikaros, a suspected inhibitor of PU.1 expression, should be specifically
corecruited to CE7-CE5 under conditions where these elements act as enhancers, we tested
the effect of neutralizing Ikaros in distinct cellular contexts, by transfecting Sfpi1 cis-
element driven luciferase reporters into B and myeloid cells with empty vector or the
“Plastic” dominant negative mutant of Ikaros. Figure 4d shows that indeed, cotransfection of
B-lineage cells with Plastic to neutralize endogenous Ikaros enhances reporter expression
driven by the URE (L98), consistent with a repressive role for Ikaros in these cells. In
contrast, however, cotransfection with Plastic strongly reduced the activity of the L98 and
L7-5 reporters in myeloid cells (Fig. 4e). Thus, via co-occupancy of CE5 and CE7/6 with
PU.1, Ikaros is a positive regulator of Sfpi1 in macrophages.
Concluding remarks
These results show that the PU.1 and Ikaros factors can act both as collaborators and as
antagonists in different cellular contexts, based on their cell-type-specific recruitment to
distinct subsets of their potential DNA target sites (Fig. 4f). The sites examined here for
lineage-specific differential recruitment of PU.1 and Ikaros are all conventionally
recognizable based on established position weight matrices, but engagement by these factors
is highly context dependent. At the myeloid-specific cis-regulatory elements of Sfpi1,
neither PU.1 nor Ikaros is sufficient to establish binding in the NFS-25 pre-B or Adh.2C2
pro-T cell lines, yet these elements can mediate potent positive regulation in myeloid cells
dependent on both PU.1 and Ikaros. Crucially, the ability of Ikaros to bind with PU.1 at the
CE8-CE9 elements themselves is associated with opposite functional consequences in B and
myeloid cells. Thus, not only can lineage determinants affect when and where Ikaros will
bind DNA, but these distinct patterns of recruitment confer an additional layer of cell-type-
specific regulatory interaction which allows Ikaros’ functional contributions to be reversed
in distinct developmental contexts.
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The Sfpi1fragment CE5-CE3 is a myeloid restricted enhancer. (a) A schematic showing the
UCSC mammalian conservation track with genome alignment of the ~18 kb upstream
region of the Sfpi1 gene is shown. Regions used in reporter constructs are depicted. Reporter
constructs were designed as described previously (14). (b) Transient transfection assays
showing Sfpi1 reporter activity in NFS-25 pre-B-cells and RAW264.7 macrophages. Data
represent the average fold difference relative to L1. NFS-25 data are from five independent
experiments. RAW264.7 data shown are from a single representative experiment performed
in triplicate. Error bars represent standard deviations. Cells were transfected using FuGENE
at a 3:1 DNA:FuGENE ratio. NFS-25 cells were grown in RPMI media with 10% fetal
bovine serum, penicillin/streptomycin/glutamine, non essential amino acids, sodium
pyruvate, and 50 μM 2-mercaptoethanol. RAW264.7 cells were grown in DMEM media
with 10% fetal bovine serum and penicillin/streptomycin/glutamine. Transfected cells were
harvested 30-48 hours post transfection. Cells were cotransfected with pRL-CMV and
lysates were analyzed using Promega’s Dual Luciferase system. (c) The CE5-CE3 fragment
is a myeloid specific enhancer when integrated into chromatin. Cell lines were stably
transfected with the L9-6 and L9-3 constructs depicted in Fig 1A. Bars show the geometric
mean of six independent mixed pools (dots) of stably transfected cells 30 days post
transfection. Data are reported as relative light units (RLU). P-value is from student’s T-test
of log10 transformed data. FuGENE:DNA complexes were formed then the same complexes
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were aliquot to 6 well plates containing either NFS-25 or RAW264.7 cells. For stable
transfections, Sfpi1 reporters were linearized with Not I prior to transfection. The renilla
luciferase was cloned into Invitrogen’s pTracer EF/Bsd A and the construct was linearized
with Fsp I for cotransfection with Sfpi1 reporters. Cells were selected with 5-15 μg/ml of
Blasticidin for their duration in culture, beginning one day post transfection. (d)
Multigenome alignments and transcription factor target site prediction analysis of the CE5
and CE7/6 regions are shown. TRANSFAC analysis was performed through the Biobase
TRANSFAC suite’s MATCH tool (https://portal.biobase-international.com/cgi-bin/portal/
login.cgi). Predicted hematopoietic transcription factors with matrix similarity matches
above 0.9 are shown (black). Some matches below 0.9 are also shown (gray). CBF = Core
Binding Factor sites for the Runx family. “Ets” labeled sites are general Ets family sites that
potentially bind to multiple Ets family factors. Asterisks mark conserved sites present in
only 4/6 aligned sequences. All other sites are present in all six sequences. The boxed
sequence shows a region of CE5 with a PU.1 target site adjacent to a specifically predicted
Ikaros target site. The red bar represents the DNA probe CE5-P2 designed for gel shift
assays (Fig. 3).
Zarnegar and Rothenberg Page 9














ChIP analysis reveals restricted and cell-type-specific PU.1 and Pol II binding. A schematic
of the regions examined in the ChIP assays is shown. The Conserved Elements are labeled
below and approximate locations of forward primers used for QPCR analysis are labeled
above. (a), Anti-PU.1 ChIP analyses are shown. ChIP assays were performed using anti-PU.
1 antibody (sc-352 from Santa Cruz). ChIP assays were performed based on Upstate’s
protocol exactly as described previously (14). Data shown in all ChIP panels are from three
or more independent experiments. Orange and purple bars in each panel show data for
positive control regions of reported PU.1 target genes Mef2c and Il7r. Panels with red bars
are from myeloid cells (RAW264.7). Panels with blue bars are from pre-B-cells (NFS-25).
Panels with green bars represent data from pro-T-cells (Adh.2C2). Primer pairs used for
each region are labeled on the x-axis and the primer sequences are reported in (14). ChIP
enriched DNA was analyzed by QPCR in triplicate for each experiment. Individual ChIP
experiments were normalized first to input DNA then normalized against a region that
lacked enrichment to provide relative fold enrichment. Independent experiments were then
averaged. Error bars show standard deviations. Iterative one-way ANOVA was used to
Zarnegar and Rothenberg Page 10













analyze ChIP data. ANOVA was initially performed with all regions. If ANOVA generated
a p-value < 0.01, data for “regions of interest” were removed from the initial ANOVA test
group and ANOVA was repeated on data from the remaining regions until these generated
p>0.1. The regions remaining in the test group that lacked a statistically significant
enrichment difference were then used as a control group against which to compare the
removed “regions of interest” individually by T-tests. The resulting p-values were adjusted
using the Bonferroni correction method and regions with p < 0.0005 were marked by
asterisks in ChIP data figures. (b) Elf-1 ChIP assays using anti-Elf-1 antibody sc-631 are
shown as described. (c) GABPα ChIP assays using anti-GABPα antibody sc-22810 are
shown as described. (d) Ets-1 ChIP assays using anti-Ets-1 antibodies sc-22802 and
sc-111are shown as described. (e) RNA polymerase II ChIP analyses are shown as described
using anti-RNAPoll II antibody ab5408 from AbCam.
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Cell type specific binding of Ikaros with PU.1 at Sfpi1 cis-regulatory elements. (a) Ikaros
binds the URE region in RAW264.7 and NFS-25 cells, but binds other regions with cell-
type-specificity. Ikaros ChIP assays were performed using antibodies Santa Cruz sc-13039
and Active Motif #39291. Data are presented as in Fig. 2. (b,c) The CE5 region nucleates
cell-type-specific myeloid complexes in vitro that contain PU.1 and Ikaros proteins. (b)
Probe CE5-P2 (see Fig. 1d) and CE5-P2m2 (Ikaros site mutated; see Fig. 4a for mutated
sequence) were radiolabeled and incubated with nuclear extracts from RAW264.7 cells (M)
or NFS-25 cells (B). Preparation of nuclear extracts and binding conditions were described
in (14). Complexes were resolved by 6% SDS PAGE, dried, and then exposed to film.
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Myeloid specific complexes are labeled M1, M2, and M3. Anti-PU.1 and anti-Ikaros
antibodies used in gel shift experiments are sc-352 and Active Motif #39291, respectively.
The overlapping PU.1/Ikaros binding site was mutated in probe CE5-P2m1. The exact
sequences mutated for m1 and m2 are shown in red in the schematic in Fig. 4a. Competitor
DNA probes were used at 250 fold molar excess; 4 μg of antibodies were used as labeled.
(c) PU.1 can direct formation of a PU.1 and Ikaros containing complex on probe CE5-P2.
TnT Couple Quick Transcription/Translation system (Promega # L1171 and L2081) was
used to generate PU.1, Ikaros, or Plastic proteins. RAW264.7 nuclear extract was included
(lane 1) for comparison. All other lanes contained equal volumes of reticulocyte lysate
(treated or untreated). For treated lysates, 1 μg of plasmid DNA was incubated with lysates
to generate proteins following manufacturer’s protocol. Ten μg of total lysate were run per
lane. (d) Western blot of Ikaros and Sp1 protein. Nuclear extracts (2-8 μg) from Adh.2C2
and Raw264.7 cells were separated on an 8% SDS-PAGE gel. This blot had been previously
probed for Sp1 and was shown in (14). The blot was stripped and reprobed here with anti-
Ikaros antibody (sc-13039). (e) Adh.2C2 cells transduced with PU.1 retroviral vector
express high levels of PU.1 mRNA. Retroviral vector supernatants were prepared by
transfection of pMX-PU.1-IRES-hCD8 plasmid into Phoenix packaging cells with FUGENE
6 reagent. Virus particle-containing medium was collected at 48-72 hours post transfection.
Adh.2C2 cells were subsequently transduced to express PU.1 using the TAKARA
RetroNectin method. RNA was prepared using Trizol and manufacturer’s protocol. cDNA
were prepared from RNA using the Superscript III system (Invitrogen #18080-400), then
analyzed for PU.1 sequence by quantitative real-time PCR. PU.1 levels were normalized
against GAPDH. Data are plotted on a log10 scale. (f) Forced expression of PU.1 in
immature T-cells permits site-restricted PU.1 binding. PU.1 ChIP experiments are shown as
described previously. Data shown are from five independent transduction and ChIP
experiments. (g and h) Ectopic PU.1 expression facilitates restricted recruitment of Ikaros
(g) and Pol II (h) to the PU.1 target regions CE9 and IL7r (black arrows). Data shown are
from two independent experiments. *p<0.0005. **p<0.002.
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PU.1 and Ikaros activate Sfpi1 enhancers in myeloid cells, but Ikaros suppresses the URE
enhancer in pre-B-cells. (a) PU.1 and Ikaros target sites in CE5 are required for enhancer
activity in RAW264.7 myeloid cells. Schematic shows the CE5 region spanning the CE5-P2
probe and flanking sequence. Nucleotides mutated in the CE5 region of the L5-3 Sfpi1
reporters are shown in red. Data show the average fold increases in activity of L5-3 and
mutated reporters relative to L1, with error bars representing standard deviations. Data are
from three independent experiments each performed in duplicate. Reporter plasmids (4 μg)
were cotransfected with 0.25 μg of control plasmid pCMV-RL into 5-6 million cells. For
transfection conditions see below. Cells were harvested ~24 hours post transfection for
analysis. (b) Anti-PU.1 morpholino antisense oligonucleotides can knock down PU.1 protein
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expression. 32Dcl5 myeloid precursor cells were used to test the morpholinos and were
grown in RPMI medium supplemented with IL-3. Morpholinos E1, overlaps exon1/intron1
boundary; and E2, overlaps exon2/intron2 boundary were ordered from Gene Tools, Inc.:
anti-PU.1 (E2) GAGGACCAGGTACTCACCGCTATG; anti-PU.1 (E1)
GTAGTGAAGCCCCAGTACTCACAGG; Standard Control oligo
CCTCTTACCTCAGTTACAATTTATA. 32Dcl5 cells were nucleofected with 2 picomoles
of morpholinos using Solution-V kits and program E-32. Cell samples were harvested for
analysis at 24 and 48 hours. The Western blot was probed using anti-PU.1 antibody
(sc-5948) and anti-Ets-1 (sc-350) as a control. (c) PU.1 knockdown abolishes L7-5 reporter
activity. (d) Ikaros contributes to myeloid enhancer activity in RAW264.7 cells. (e) Ikaros
suppresses URE enhancer activity in NFS-25 pre-B-cells. Raw264.7 and NFS-25 cells were
cotransfected with Sfpi1 reporters and pEF empty vector (EV) or pEF-Plastic (Ikaros
dominant negative). Transfection data in each panel (c-e) are from three independent
experiments performed in duplicate. Error bars show standard deviations. Data are shown as
fold difference relative to L1+Control (c) or L1+pEF (d,e). RAW264.7 cells were
transfected with Sfpi1 reporters and 2 picomoles of standard control morpholino or anti-PU.
1 morpholino. Transfection and cotransfection were performed by Nucleofection (Lonza/
Amaxa) using Solution-V kits and program D-32 for RAW264.7 cells or program A-33 for
NFS-25 cells. (f) Schematic depicts cell-type-specific patterns of PU.1 and Ikaros binding to
Sfpi1 cis-elements and the differences in their functional consequences for transcriptional
control.
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